HAISCO HAISCO ot 海思科HSK3486 海思科策略会 ---研发布局概览--- 周峰 博士 国际合作部 2018年4月19日 ্তি Agenda | --- | --- | |--------------------------|-------| | | | | 全球医药行业研发进展概览 | | | | | | 海思科创新药布局 | | | 海思科仿制药布局 | | | 海思科研发布局总结 | | Agenda | --- | --- | |--------------------------|-------| | | | | 全球医药行业研发进展概览 | | | 海思科创新药布局 | | | | | | 海思科仿制药布局 | | | 海思科研发布局总结 | | 国际 屈思科·研发 2004-2014全球制药行业综述 250 2014 Industry 225 Global pharmaceutical sales (US$BN) 1043 200 Total R&D expenditure (US$BN) 74 175 150 138.5 125 100 2004 2005 2006 20 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a year-on-year growth of 25%[21] - The company's operating revenue for the first half of 2021 was ¥1,276,189,009.59, a decrease of 12.08% compared to the same period last year[26] - Net profit attributable to shareholders increased by 40.15% to ¥320,268,410.66, while the net profit excluding non-recurring gains and losses decreased by 77.80% to ¥26,347,728.72[26] - The company's operating revenue for the reporting period was ¥1,276,189,009.59, a decrease of 12.08% compared to ¥1,451,477,269.51 in the same period last year[52] - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥369,669,879.00, a 253.39% improvement from -¥241,007,593.99[52] - The company reported a net profit of 1,162 million RMB, reflecting a growth of 34% year-on-year[138] - The company reported a significant increase in investment income, reaching CNY 5,440,841.06, compared to a loss of CNY 16,002,905.80 in the first half of 2020[182] - The total comprehensive income for the first half of 2021 was CNY 115,690,152.48, down from CNY 223,185,286.27 in the previous year[183] User Engagement and Market Expansion - User data indicates that the company has expanded its customer base by 15%, reaching a total of 500,000 active users by the end of June 2021[21] - User data indicates a steady increase in customer engagement, with a reported 15% rise in active users compared to the previous year[136] - The company is focusing on expanding its market presence through new product development and technological advancements in the upcoming quarters[137] - The company is actively pursuing market expansion strategies to enhance its presence in both domestic and international markets[77] - The company aims to explore potential mergers and acquisitions to strengthen its market position and expand its product portfolio[196] Research and Development - The company has allocated 200 million RMB for research and development in new technologies, focusing on improving drug efficacy and safety[21] - The company is focused on innovation and has a number of projects in both innovative drugs and high-end generic drugs under research[37] - The company has 5 innovative drugs in clinical stages, with the first innovative drug, HSK-3486, successfully launched in 2020[38] - The company's R&D investment increased by 12.61% to ¥341,845,852.57 from ¥303,569,807.97 year-on-year[52] - The company is investing in research and development, allocating 10% of its revenue towards innovative healthcare solutions[137] - Ongoing research and development efforts are aimed at innovating new drug formulations to meet market demands[140] Product Development and Innovation - New product development includes the launch of three innovative drugs, which are expected to contribute an additional 300 million RMB in revenue by the end of 2021[21] - The company launched its first self-developed intravenous anesthetic,环泊酚注射液, approved for sedation during gastrointestinal endoscopy[34] - The company is advancing multiple innovative drug projects, with ongoing clinical trials for several key products targeting various therapeutic areas[46] - New product development includes a range of injectable solutions and vitamins, which are expected to enhance the product portfolio[139] Financial Stability and Investments - The total assets at the end of the reporting period were ¥4,927,454,988.39, a decrease of 1.38% from the end of the previous year[26] - The company's total liabilities decreased to CNY 2,073,150,118.43 from CNY 2,141,839,072.61, a reduction of approximately 3.2%[171] - The company's equity attributable to shareholders decreased to CNY 2,830,001,583.88 from CNY 2,902,376,915.50, a decline of about 2.5%[171] - The company reported a significant increase in prepayments, which rose to CNY 63,229,302.07 from CNY 37,649,308.73, marking an increase of approximately 68.2%[168] - The company has ongoing construction projects, including the Chengdu headquarters and research center, with total investments of CNY 393.74 million to date[68] Regulatory and Operational Risks - The management has identified regulatory risks as a significant concern, which could impact operational costs and profitability in the future[21] - The company faces risks related to new drug development, including high investment costs and long cycles, which may impact economic returns if regulatory approvals are not obtained[80] - The average profit margin in the pharmaceutical industry may decline due to ongoing drug price reductions and increased competition, particularly affecting generic drugs[81] Environmental Compliance - The company has achieved a 100% compliance rate with environmental impact assessments and the "three simultaneous" system for all approved projects[103] - The company has implemented a comprehensive air pollution control system, including low-nitrogen combustion devices and activated carbon adsorption for organic waste gas treatment[102] - The company has established a comprehensive emergency response mechanism for environmental incidents, conducting multiple drills to enhance response capabilities[106] Shareholder and Stock Information - The total number of shares decreased from 1,074,479,620 to 1,074,144,220, reflecting a reduction of 335,400 shares[145] - Major shareholder Wang Junmin holds 37.20% of the shares, totaling 399,550,400 shares, with 99,887,600 shares pledged[153] - The company’s stock incentive plan is executed according to the established guidelines, ensuring compliance with regulations[150] Future Outlook - The company has set a future outlook with a revenue target of 2.5 billion RMB for the full year 2021, which would require a growth rate of approximately 20% in the second half[21] - Future guidance suggests a continued upward trend in revenue, with an expected growth rate of approximately 20% for the next fiscal year[138] - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[196]